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The data presented in this article are related to the research article
entitled “The Diagnostic Value of Rescaled Renal Biomarkers Serum
Creatinine and Serum Cystatin C and their Relation with Measured
Glomerular Filtration Rate” (Pottel et al. (2017) [1]). Data are pre-
sented demonstrating the rationale for the normalization or rescalingvier Inc. This is an open access article under the CC BY license
/j.cca.2017.06.005
(H. Pottel).
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Dof serum cystatin C, equivalent to the rescaling of serum creatinine.
Rescaling biomarkers brings them to a notionally common scale with
reference interval [0.67–1.33]. This article illustrates the correlation
between rescaled biomarkers serum creatinine and serum cystatin C
by plotting them in a 2-dimensional graph. The diagnostic value in
terms of sensitivity and speciﬁcity with measured Glomerular Fil-
tration Rate as the reference method is calculated per age-decade for
both rescaled biomarkers. Finally, the interchangeability between
detecting impaired kidney function from renal biomarkers and from
the Full Age Spectrum FAS-estimating GFR-equation and measured
GFR using a ﬁxed and an age-dependent threshold is shown.
& 2017 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Renal Physiology
ore speciﬁc sub-
ject areaRenal biomarkers serum creatinine (Scr) and serum cystatin C (ScysC) and their
relation with directly measured glomerular ﬁltration rate (mGFR)ype of data Assay results for serum creatinine, serum cystatin C and directly measured
glomerular ﬁltration rate from various reference methods, demographic dataow data was
acquiredDiagnostic assays, accepted reference methods for GFRata format Data are presented in graphs and tables in analyzed format
xperimental
factorsAll biomarker assays are calibrated against the international standard or gold
standard method (IDMS for Scr). All methods for GFR are reference methods with
accepted sufﬁcient accuracy.xperimental
featuresSee Table 1 in reference [1].ata source
locationSee Table 2 in reference [1]. All data cohorts were presented in previous studies.ata accessibility The data used in this article are obtained by pooling different cohorts which are
not available in a public repository, and were received by the mentioned insti-
tutes for the purpose of this study. The data from the CRIC Study reported here
were supplied by the NIDDK Central Repositories. [1]The data are presented in
summary tables and graphs within this article.Value of the data
 The data present the rationale for the choice of the rescaling factor for serum cystatin C.
 Rescaling brings the biomarker to a notionally common scale making its interpretation easy with
reference to the reference interval [0.67–1.33].
 The upper limit of the reference interval (1.33) is used as a threshold to detect impaired kidney
function and this is compared to the deﬁnition of impaired kidney function based on a ﬁxed and
age-dependent threshold for GFR.
 These data give new insights into the relation between renal biomarkers and measured GFR.
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1.1. Rationale for the rescaling of serum cystatin C (ScysC)
Analogous to the normalization or rescaling of serum creatinine (Scr), the normalization or rescaling factor(s) for ScysC is
deﬁned as the mean (or median) of the ScysC-distribution(s) for healthy subjects. The rescaling factors have previously been
deﬁned as QcysC ¼ 0.82 mg/L for subjects aged o 70 years and QcysC ¼ 0.95 mg/L for subjects aged Z 70 years [2]. In this
article, data and a new analysis are presented to further support these choices for the rescaling of ScysC.
Only ‘healthy’ subjects were selected, that is, a subgroup is selected from the total collection of 8584 subjects, obtained
from the normal population and from nephrology clinics. First, it was required that Scr/Qcrea r 1.33, or, only subjects with
‘normal’ Scr-values were selected. Qcrea-values for Scr have been reported for children and adolescents [3,4]. For adults, Qcrea ¼
0.70 mg/dL is used for females and Qcrea ¼ 0.90 mg/dL for males. This selection requirement reduces the total dataset from
8584 to 5352 patients. The additional requirement that mGFR Z 60 mL/min/1.73 m² further reduces the dataset from 5352 to
4907. Table 1 shows the numbers, mean, median, standard deviation (SD) and interquartile range (IQR) per age-decade for
ScysC in this healthy subjects subgroup.
For each decade, a truncated cumulative Gaussian ﬁt was performed to determine the mean and standard deviation of the
sample (Fig. 1 and Table 1). The dotted line in Fig. 1 represents the linear increase in normalization factor beyond the age of 70
years. In the FAS-cystatin C article [2] it was shown that there was no added value to using this (dotted) straight line ﬁt for the
normalization factor beyond 70 years, therefore, to keep it simple, the value of 0.95 mg/L was chosen as the rescaling factor for
ScysC for ages 4 70 years.
1.2. Rescaled biomarkers
The FAS-equation has been designed for Scr/Qcrea but it has recently been shown that it can also be used for ScysC/QcysC and
for the combination of both normalized biomarkers [2,5]. The fact that the same equation can be used to estimate mGFR from
renal biomarkers also means that it is expected that Scr/Qcrea E ScysC/QcysC.
Fig. 2 is a scatterplot of ScysC/QcysC against Scr/Qcrea, using the corresponding age/sex dependent Qcrea-values and QcysC-
values, for all 8584 subjects. The diagonal line is the identity line, representing equal rescaled biomarkers. The scatter around
the identity line indicates the amount to which the rescaled biomarkers deviate from each other. The overall Pearson corre-
lation coefﬁcient (r) between the rescaled biomarkers is 0.87 (p o 0.0001, n ¼ 8584) and Lin's Concordance Correlation
Coefﬁcient is 0.857 with 95%CI [0.852–0.863]. Lin's CCC evaluates the degree to which pairs of observations fall on the diagonal
or identity line through the origin. For children, r ¼ 0.85, Lin's CCC ¼ 0.828 (n ¼ 767); for adults, r ¼ 0.87 and Lin's CCC ¼
0.861 (n ¼ 6068) and for older adults r ¼ 0.88, Lin's CCC ¼ 0.852 (n ¼ 1749).
1.3. diagnostic value of the single rescaled biomarkers
The diagnostic value of the single renal biomarkers is presented in the Tables 2 and 3. The ﬁxed threshold for mGFR of
60 mL/min/1.73 m² is compared to the age-dependent threshold COAD ¼ 107.3/1.33 [ × 0.988(Age-40) if Age 4 40 years] [1,6].
1.3.1. Serum creatinine
Sensitivity (S) and Speciﬁcity (Sp) in Fig. 3a-b are calculated as follows:
a) in case a true positive test result is deﬁned as Scr/Qcrea 4 1.33 in the mGFR o 60 subgroup, and a true negative test result
is deﬁned as Scr/Qcrea r 1.33 in the mGFR Z 60 subgroup. E.g. in the age-group 2–10 years, S ¼ 28 / (28 þ 0) ¼ 100% andTable 1
Serum cystatin C concentrations for subjects with Scr/Qcrea r 1.33 and mGFR Z 60 mL/min/173 m².
Age Group n mean median SD IQR
2–10 170 0.94 0.92 0.18 0.24
10–20 352 0.96 0.93 0.22 0.29
20–30 122 0.84 0.81 0.17 0.18
30–40 293 0.79 0.78 0.14 0.16
40–50 432 0.81 0.80 0.16 0.21
50–60 1543 0.76 0.74 0.15 0.17
60–70 1317 0.81 0.78 0.16 0.19
70–80 528 0.89 0.88 0.15 0.19
80–90 147 0.96 0.96 0.14 0.19
4 90 3 1.04 1.01 0.06 0.11
4907
Fig. 2. : Rescaled biomarker ScysC/QcysC against Scr/Qcrea for n¼8584 subjects. The diagonal line is the identity line. The
vertical and horizontal dotted lines correspond to ScysC/QcysC and Scr/Qcrea equal to 0.67 and 1.33 respectively and deﬁne the
area of ‘normal’ biomarkers. Rescaled biomarker values o 0.67 are ‘Low’ and 4 1.33 are indicated as ‘high’.
Fig. 1. : Mean and reference intervals for serum cystatin C (mg/L) for age decades (years). The solid horizontal line corresponds
with the choice of the normalization factor, 0.82 up to 70 years and 0.95 beyond 70 years of age. The vertical bars represent the
interval from 2.5th Percentile (Pct) to 97.5th Pct as obtained from the Gaussian distribution for each decade.
H. Pottel et al. / Data in Brief 14 (2017) 763–772766Sp ¼ 170 / (170 þ 48) ¼ 78.0%; in the age-group 80–90 years, S ¼ 180 / (180 þ 96) ¼ 65.2% and Sp ¼ 147 / (147 þ 10) ¼
93.6%. Reversing the role of Scr/Qcrea and mGFR, we ﬁnd for the 2–10 year age-group: S ¼ 28/76 ¼ 36.8% and Sp ¼ 170/
170 ¼ 100%; in the age-group 80–90 years, we have S ¼ 180/190 ¼ 94.7% and Sp ¼ 147/243 ¼ 60.5%.
b) in case a true positive test result is deﬁned as Scr/Qcrea 4 1.33 in the mGFR o COAD subgroup, and a true negative test
result is deﬁned as Scr/Qcrea r 1.33 in the mGFR Z COAD subgroup. E.g. in the age-group 2–10 years, S ¼ 61 / (61 þ 20) ¼
75.3% and Sp ¼ 220 / (220 þ 37) ¼ 85.6%; in the age-group 80–90 years, S ¼ 180 / (180 þ 96) ¼ 65.2% and Sp ¼ 147 /
(147 þ 10) ¼ 93.6%. Reversing the role of Scr/Qcrea and mGFR, we ﬁnd for the 2–10 year age-group: S ¼ 61/76 ¼ 80.3%
and Sp ¼ 150/170 ¼ 88.2%; in the age-group 80–90 years, we have S ¼ 153/190 ¼ 80.5% and Sp ¼ 220/243 ¼ 90.5%.
1.3.2. Serum cystatin C
Sensitivity (S) and Speciﬁcity (Sp) are calculated as follows:
a) in case a true positive test result is deﬁned as ScysC/QcysC 4 1.33 in the mGFR o 60 subgroup, and a true negative test
result is deﬁned as ScysC/QcysC r 1.33 in the mGFR Z 60 subgroup. E.g. in the age-group 2–10 years, S ¼ 27 / (27 þ 1) ¼
96.4% and Sp ¼ 157 / (157 þ 61) ¼ 72.0%; in the age-group 80–90 years, S ¼ 182 / (182 þ 94) ¼ 65.9% and Sp ¼ 152 /
(152 þ 5) ¼ 96.8%. Reversing the role of ScysC/QcysC and mGFR, we ﬁnd for the 2–10 year age-group: S ¼ 27/88 ¼ 30.7%
and Sp ¼ 285/290 ¼ 98.3%; in the age-group 80–90 years, we have S ¼ 182/187 ¼ 97.3% and Sp ¼ 152/246 ¼ 61.8%.
Table 2a
Frequency of patients with rescaled Serum creatinine r and 4 1.33 in the subgroups deﬁned by mGFR (ﬁxed and age-dependent threshold COAD).
Scr/Qcrea r 1.33 Scr/Qcrea 4 1.33
Age Group mGFRo 60 mGFRZ 60 mGFRoCOAD mGFRZCOAD Total mGFRo 60 mGFRZ 60 mGFRoCOAD mGFRZCOAD Total Grand Total
[2–10[ 0 170 20 150 170 28 48 61 15 76 246
[10–20[ 6 352 68 290 358 147 94 215 26 241 599
[20–30[ 4 122 19 107 126 72 29 85 16 101 227
[30–40[ 1 293 27 267 294 151 94 205 40 245 539
[40–50[ 17 432 70 379 449 227 125 297 55 352 801
[50–60[ 61 1543 105 1499 1604 385 142 441 86 527 2131
[60–70[ 103 1317 111 1309 1420 683 168 681 170 851 2271
[70–80[ 139 528 57 610 667 554 64 480 138 618 1285
[80–90[ 96 147 23 220 243 180 10 153 37 190 433
Z 90 17 3 5 15 20 32 0 27 5 32 52
444 4907 505 4846 5351 2459 774 2645 588 3233 8584
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Table 2b
Frequency of patients with rescaled Serum cystatin C r and 4 1.33 in the subgroups deﬁned by mGFR (ﬁxed and age-dependent threshold COAD).
ScysC/QcysC Z 1.33 ScysC/QcysC 4 1.33
Age Group mGFRo 60 mGFRZ 60 mGFRoCOAD mGFRZCOAD Total mGFRo 60 mGFRZ 60 mGFRoCOAD mGFRZCOAD Total Grand Total
[2–10[ 1 157 20 138 158 27 61 61 27 88 246
[10–20[ 5 285 39 251 290 148 161 244 65 309 599
[20–30[ 4 133 24 113 137 72 18 80 10 90 227
[30–40[ 7 352 62 297 359 145 35 170 10 180 539
[40–50[ 22 500 103 419 522 222 57 264 15 279 801
[50–60[ 53 1595 110 1538 1648 393 90 436 47 483 2131
[60–70[ 113 1352 122 1343 1465 673 133 670 136 806 2271
[70–80[ 229 570 103 696 799 464 22 434 52 486 1285
[80–90[ 94 152 22 224 246 182 5 154 33 187 433
Z 90 14 3 3 14 17 35 0 29 6 35 52
542 5099 608 5033 5641 2361 582 2542 401 2943 8584
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Fig. 3. a: Sensitivity and Speciﬁcity per age-category. Solid circles correspond to Scr/Qcrea as the test result (positive when 4
1.33, negative when r 1.33) and diseases status deﬁned by the ﬁxed mGFR threshold of 60 mL/min/1.73 m². Open circles
correspond to the reversed situation, that is, mGFR as the test result (positive when mGFR o 60 and negative when mGFR Z
60) and disease status deﬁned by the Scr/Qcrea threshold of 1.33. b: Sensitivity and Speciﬁcity per age-category. Solid circles
correspond to Scr/Qcrea as the test result (positive when 4 1.33, negative when r 1.33) and diseases status deﬁned by the age-
dependent mGFR threshold COAD. Open circles correspond to the reversed situation, that is, mGFR as the test result (positive
when mGFR o COAD and negative when mGFR Z COAD) and disease status deﬁned by the Scr/Qcrea threshold of 1.33.
H. Pottel et al. / Data in Brief 14 (2017) 763–772 769b) in case a true positive test result is deﬁned as ScysC/QcysC 4 1.33 in the mGFR o COAD subgroup, and a true negative test
result is deﬁned as ScysC/QcysC r 1.33 in the mGFR Z COAD subgroup. E.g. in the age-group 2–10 years, S ¼ 61 / (61 þ
20) ¼ 75.3% and Sp ¼ 138 / (138 þ 27) ¼ 83.6%; in the age-group 80–90 years, S ¼ 154 / (154 þ 22) ¼ 87.5% and Sp ¼
224 / (224 þ 33) ¼ 87.2%. Reversing the role of ScysC/QcysC and mGFR, we ﬁnd for the 2–10 year age-group: S ¼ 61/88 ¼
69.3% and Sp ¼ 138/158 ¼ 87.3%; in the age-group 80–90 years, we have S ¼ 154/187 ¼ 82.4% and Sp ¼ 224/246 ¼ 91.1%
(Fig. 4).
1.4. Interchangeability between biomarkers and mGFR / FAS-eGFR
Comparing (Scr/QcreaþScysC/QcysC)/2 using the threshold of 1.33 with mGFR using the ﬁxed threshold of 60 mL/min/
1.73 m², for the complete n ¼ 8584 dataset, to detect renal impairment, we have (Table 3a):
Exact McNemar's test: p o 0.0001. % agreement ¼ (5067 þ 2488) / 8584 ¼ 88.0%.
Comparing (Scr/QcreaþScysC/QcysC)/2 using the threshold of 1.33 with mGFR using an age-dependent threshold, for the
complete n ¼ 8584 dataset, to detect renal impairment, we have (Table 3b):
Exact McNemar's test: p ¼ 0.1027. % agreement ¼ (5043 þ 2711) / 8584 ¼ 90.3%.
Using the FAScombi equation to calculate eGFR from both Scr/Qcrea and ScysC/QcysC, the following table is obtained when
comparing FAS-eGFR using the age-dependent threshold with the combined biomarker value (Scr/QcreaþScysC/QcysC)/2 using
the threshold of 1.33 (Table 4):
In Fig. 5a-b, the raw mGFR-values are plotted against age, for the subgroups deﬁned by (Scr/QcreaþScysC/QcysC)/2 below
and above the threshold of 1.33, together with the ﬁxed threshold for mGFR ¼ 60 mL/min/1.73 m² and the age-dependent
threshold obtained from the FAS-equation with (Scr/QcreaþScysC/QcysC)/2 ¼ 1.33. These ﬁgures correspond to the Tables 3a and
b.
Fig. 4. a: Sensitivity and Speciﬁcity per age-category. Solid circles correspond to ScysC/QcysC as the test result (positive when 4
1.33, negative when r 1.33) and disease status deﬁned by the ﬁxed mGFR threshold of 60 mL/min/1.73 m². Open circles corre-
spond to the reversed situation, that is, mGFR as the test result (positive when mGFR o 60 and negative when mGFR Z 60) and
disease status deﬁned by the ScysC/QcysC threshold of 1.33. b: Sensitivity and Speciﬁcity per age-category. Solid circles correspond
to ScysC/QcysC as the test result (positive when 4 1.33, negative when r 1.33) and diseases status deﬁned by the age-dependent
mGFR threshold COAD. Open circles correspond to the reversed situation, that is, mGFR as the test result (positive when mGFR o
COAD and negative when mGFR Z COAD) and disease status deﬁned by the ScysC/QcysC threshold of 1.33.
Table 3a
2×2 frequency table comparing measured GFR (with ﬁxed threshold of 60 mL/min/1.73 m²) with the average of the biomarkers
(with threshold 1.33).
mGFR
Z 60 o 60 Total
Average of Biomarkers r 1.33 5067 415 5482
4 1.33 614 2488 3102
Total 5681 2903 8584
H. Pottel et al. / Data in Brief 14 (2017) 763–7727702. Experimental design, materials and methods
This is a retrospective study, where the data presented here were collected from 12 previously
published cohorts (grand total of 8584 patients) and centralized for pooled data-analysis. Assay data
for Scr and ScysC, together with measured GFR, age, sex were centralized for the data-analysis. The
total number of patients was subdivided into subgroups corresponding with age-decades with the
aim to perform a data-analysis of the diagnostic value (in terms of sensitivity and speciﬁcity) of the
Table 3b
2×2 frequency table comparing measured GFR (with age-dependent threshold) with the average of the biomarkers (with
threshold 1.33).
mGFR
Z COAD o COAD Total
Average of Biomarkers r 1.33 5043 439 5482
4 1.33 391 2711 3102
Total 5434 3150 8584
Table 4
2×2 frequency table comparing (FAS) estimated GFR (with age-dependent threshold) with the average of the biomarkers (with
threshold 1.33).
FAS-eGFR
Z COAD o COAD Total
Average of Biomarkers r 1.33 5482 0 5482
4 1.33 0 3102 3102
Total 5482 3102 8584
Fig. 5. a-b. Measured GFR against age for n ¼ 5482 subjects with the mean of both biomarkers r1.33 (top), and n ¼ 3102
with the mean of both biomarkers 41.33 (bottom). The horizontal red line is the ﬁxed GFR-threshold of 60 mL/min/1.73 m²
and the curved red line is the age-dependent threshold COAD.
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H. Pottel et al. / Data in Brief 14 (2017) 763–772772biomarkers per age-decade. Sensitivity and speciﬁcity were calculated with reference to measured
GFR (ﬁxed and age-dependent threshold), and with reference to the rescaled biomarker threshold of
1.33.
Scr was traceable to the gold standard Isotope Dilution Mass Spectrometry method, ScysC was
obtained from assays calibrated to the international standard or ScysC was recalculated against the
calibrator and measured GFR was obtained from accepted reference methods, as described in the
main article [1].Acknowledgements
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